Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VM100 Nutritional Supplement
- Development stage
- Unknown
- Lead developer
- University of Florida
- Administration
- Oral
01
Overview
VM100 Nutritional Supplement is an investigational dietary supplement formulated with ten naturally derived ingredients designed to support the pathophysiology of Duchenne muscular dystrophy (DMD). Developed by the University of Florida, VM100 is formulated as an oral drink using a proprietary technology to enhance the bioavailability of its active components. It is designed to target key pathological features of DMD, including inflammation, mitochondrial impairment, and oxidative stress in both skeletal muscle and brain tissue. VM100 is being evaluated in clinical trials to assess its potential to improve physical symptoms (such as endurance and fatigue), cognitive function, mood, and overall quality of life in patients with DMD.
Beyond the preview
Go deeper on VM100 Nutritional Supplement.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VM100 Nutritional Supplement.